Contribution: Industrial Research Assistance Program – Youth Employment Program
CCOA Therapeutics Inc
$30,000.00
YOUTH Rapid Prophylaxis Development against COVID-19
EF 2020-21 · 2020-06-15
Résumé
This project is to develop community-based prophylaxis for COVID-19 via our newly developed Angiotensin-Converting Enzyme 2 (ACE2) mimetics, and to develop marketing strategy for our innovative products.
Ministère
Programme
Industrial Research Assistance Program – Youth Employment Program
Bénéficiaire
Emplacement
Toronto|Toronto, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
780647129
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2021-03-23
Agreement Number
952405
Agreement Start Date
2020-06-15
Agreement Title
YOUTH Rapid Prophylaxis Development against COVID-19
Agreement Title (French)
PEJ - Mise au point d'une prophylaxie rapide contre la COVID-19
Agreement Type
Contribution
Agreement Value
$30,000.00
Amendment Number
0
Coverage
IRAP Youth Employment Program projects stimulate wealth creation for Canada through technological innovation. | Les projets du Programme Emploi-jeunesse du PARI stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project is to develop community-based prophylaxis for COVID-19 via our newly developed Angiotensin-Converting Enzyme 2 (ACE2) mimetics, and to develop marketing strategy for our innovative products.
Description (French)
Ce projet vise à mettre au point une prophylaxie communautaire contre la COVID-19 par le biais de nos nouveaux agents mimétiques de l'enzyme 2 de conversion de l'angiotensine (ACE2), et à élaborer une stratégie de marketing pour nos produits innovants.
Expected Results
The purpose of IRAP’s Youth Employment Program is to assist in increasing the supply of highly qualified people, promoting the benefits of advanced studies, demonstrating federal leadership by investing in the skills required to meet the needs of the knowledge economy and facilitating the transition of highly skilled young people to a rapidly changing labour market.
Expected Results (French)
Le Programme Emploi-jeunesse du PARI contribue à accroître le bassin de personnes hautement qualifiées, fait la promotion des études supérieures, démontre le leadership fédéral grâce aux investissements effectués dans l’acquisition des compétences requises pour répondre aux besoins de l’économie du savoir et facilite la transition des jeunes hautement qualifiés vers un marché du travail en évolution rapide.
Federal Riding
Toronto Centre
Federal Riding (French)
Toronto-Centre
Federal Riding Number
35108
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Youth Employment Program
Program Name (French)
Programme d’aide à la recherche industrielle – Programme emploi jeunesse
Program Purpose
The purpose of IRAP’s Youth Employment Program is to assist in increasing the supply of highly qualified people, promoting the benefits of advanced studies, demonstrating federal leadership by investing in the skills required to meet the needs of the knowledge economy and facilitating the transition of highly skilled young people to a rapidly changing labour market.
Program Purpose (French)
Le Programme Emploi-jeunesse du PARI contribue à accroître le bassin de personnes hautement qualifiées, fait la promotion des études supérieures, démontre le leadership fédéral grâce aux investissements effectués dans l’acquisition des compétences requises pour répondre aux besoins de l’économie du savoir et facilite la transition des jeunes hautement qualifiés vers un marché du travail en évolution rapide.
Recipient Business Number
780647129
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
CCOA Therapeutics Inc
Recipient Operating Name
CCOA Therapeutics Inc
Recipient Postal Code
M5B 1T8
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2020-2021-Q1-952405
